UP!

CBM $59.99   View long term graphs

Cambrex Corporation
Type
Public
Traded as NYSE: CBM
S&P 600 Component
Industry Pharmaceuticals
Founded New Jersey (1981)
Headquarters East Rutherford, NJ
Key people
Steven M. Klosk, CEO, President,
Revenue Increase 433.9 million USD (2015)
Net income
Increase 57.2 million USD (2015)
Total assets Increase 505.5 million USD (2015)
Total equity Increase 310.8 million USD (2015)
Number of employees
1,200+
Website www.cambrex.com

Cambrex Corporation is a life sciences company that provides products and services for small molecule active pharmaceutical ingredients (APIs).

Cambrex has cGMP manufacturing facilities in the US (Charles City, IA), Europe (Karlskoga, Sweden, Milan, Italy and Hyderabad, India, and R&D centers in Tallinn, Estonia, Wiesbaden, Germany). The headquarters are located in East Rutherford, NJ.

In 2007, Cambrex divested their biologics business to Lonza to focus on small molecule APIs.

Cambrex was founded in 1981, when the CasChem group acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem was renamed Cambrex Corporation and became listed on NASDAQ. Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco.

Through multiple acquisitions during the late 1990s, the firm entered the bioscience and the chiral enzymatic catalyst markets. In 1998, Cambrex was listed on the NYSE. The firm acquired two contract biopharmaceutical manufacturing facilities, in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales. In 2007, the firm decided to focus on its core competencies and sold the biologics business to Lonza Group. In 2008, Prosyntest (now Cambrex Tallinn) was acquired, and Steve Klosk was appointed CEO, while remaining President. To broaden their biocatalysis platform, Cambrex acquired IEP, now known as Cambrex IEP. In 2014, they acquired Zenara Pharma to enhance its drug product formulation capabilities, including Nicotine Replacement Therapy products.Cambrex Corporation has agreed to acquire Pharma Core Inc, a private company specializing in developing, manufacturing and scaling up small molecule APIs for clinical phase projects, for approx $25 million

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2020 2020-04-30 Future report Set alerts
Q4 2019 2020-02-11 Future report Set alerts
Q3 2019 2019-10-31 0.00 0.25
Q2 2019 2019-08-07 0.74 0.46
Q1 2019 2019-05-02 0.60 0.31
Q4 2018 2019-02-13 1.44 0.04
Q3 2018 2018-11-08 0.49 0.79
Q2 2018 2018-08-02 0.74 1.21
Q1 2018 2018-05-03 0.37 0.72
Q4 2017 2018-02-08 1.27 1.20

Ratings

2016-02-11 Lower Price Target Singular Research Buy $63.00 to $60.00
2016-02-01 Initiated Coverage Sidoti Buy $60.00
2015-07-31 Reiterated Rating Longbow Research Buy $48.00 to $60.00
2015-07-21 Initiated Coverage Stephens Overweight $55.00
2015-05-29 Initiated Coverage Singular Research Buy $51.00
2015-03-31 Initiated Coverage Craig Hallum Buy $50.00
2014-08-08 Downgrade First Analysis Overweight to Equal Weight
2014-08-05 Boost Price Target Longbow Research Buy $27.00
2014-01-28 Upgrade First Analysis Equal Weight to Overweight
2008-03-24 Downgrade KeyBanc Capital Mkts Buy to Hold
2008-03-24 Downgrade First Analysis Sec Overweight to Equal-Weight
2007-11-05 Downgrade Longbow Buy to Neutral
2007-03-12 Upgrade KeyBanc Capital Mkts / McDonald Hold to Buy $26
2016-02-11 Lower Price Target Singular Research Buy $63.00 to $60.00
2016-02-01 Initiated Coverage Sidoti Buy $60.00
2015-07-31 Reiterated Rating Longbow Research Buy $48.00 to $60.00
2015-07-21 Initiated Coverage Stephens Overweight $55.00
2015-05-29 Initiated Coverage Singular Research Buy $51.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
DIXON ROSINA B 0.27%  (84226) CBM / CHD /
KLOSK STEVEN M President & CEO 0.27%  (83328) CBM / NBS /
HENDRIX LEON J JR 0.22%  (67301) CBM /
RUSSOLO PAOLO President, Cambrex Profarmaco 0.22%  (67085) CBM /
HARRIGAN KATHRYN 0.20%  (60306) CBM /
KAUFTHAL ILAN 0.19%  (59584) BTH / CBM /
SARGEN GREGORY Executive Vice President & CFO 0.16%  (50000) CBM / PPHM /
MILLER JOHN R 0.12%  (35306) CBM /
TOMBROS PETER G 0.08%  (24029) CBM / NPSP /
BETHUNE DAVID R 0.07%  (21116) CBM / FHCO /
KORB WILLIAM B 0.07%  (20562) CBM /
Cavanagh Shawn Executive Vice President & COO 0.06%  (17658) CBM /
Yanai Shlomo 0.04%  (13239) CBM / PRGO / SGNT /
Grabowsky Louis J. 0.02%  (4842) CBM / GFF / MYCC /
GLASSELL CLAES 0.01%  (3914) CBM / CERS /
Hampl Bernhard 0.01%  (2844) CBM /
BROWN GREGORY B 0.01%  (1662) CBM / NBS /

Comments